In previous studies, we showed that targeting BMI-1 with the preclinical compound PTC-209 (PTC Therapeutics) resulted in significant in vivo antitumor activity in xenograft lung cancer models characterized by low C/EBPα expression (25). The gene discussed is CEBPA; the disease is lung cancer.